Skip to content
Digistain logo

Digistain

Digistain is a YC Summer 2021 (S21) company. Based in London, England, United Kingdom. Team of 40.

  • Medical Devices

About Digistain

GPAgent's own fund-neutral profile, written from public information. Updated Oct 4, 2026.

Summary

Digistain builds a quantitative histopathology platform that gives oncologists a personalized recurrence-risk score for early-stage, HER2-negative, ER-positive breast cancer patients after surgery. The platform runs on standard FFPE tissue sections already in hospital labs, using a proprietary infrared spectral algorithm to replace the need for molecular extraction and expensive external genomic testing. It delivers risk stratification in hours rather than weeks, helping multidisciplinary teams decide whether chemotherapy is warranted without sending samples to an overseas reference lab.

Go-to-market

Digistain sells to hospital oncology and histopathology departments, with clinicians ordering the test directly through the platform; the product integrates into existing histopathology workflows without new equipment purchases.

From the Y Combinator listing

How Digistain describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow

In the global fight against breast cancer, Digistain stands at the forefront, offering a beacon of hope to millions. Our journey began at Imperial College London, where ground-breaking research gave birth to a technology poised to revolutionize breast cancer diagnostics. The Challenge: Every year, breast cancer affects 2.3 million individuals globally. Post-surgery, 60% of patients are advised to undergo genomic testing, an expensive and time-consuming process monopolized by a single lab in the U.S., costing around $4,000 and taking nearly two months. Consequently, only 5% undergo this vital testing. The rest, unable to access this crucial diagnostic step, often resort to chemotherapy—a treatment that, in one in four cases, is more harmful than the cancer itself. Our Solution: Digistain addresses this critical gap. Our technology transforms the current diagnostic process by enabling hospitals to analyze patient samples in-house using existing equipment, supplemented with our innovative technology. This approach offers near-instantaneous decision-making data, a stark contrast to the existing month-long waits. Central to our technology is a proprietary algorithm that identifies a unique spectral fingerprint of the tumour in the infrared spectrum, providing a personalized risk score. This score guides oncologists in selecting the most effective, individualized treatment plans, potentially reducing unnecessary chemotherapy and its harmful side effects. Impact and Potential: Our solution not only challenges the status quo in technology but also in accessibility. In a landmark government-commissioned study, Digistain demonstrated clinical evidence on par with the market leader, but at a fraction of the cost and time. Already making waves in clinical practice globally, with insurance reimbursement at leading cancer centers, our technology represents a paradigm shift in cancer care. Recognized by the Institute of Physics, the Royal Society, and Imperial College for our innovative contributions, and supported by entities like the NHS, Y Combinator, and the European Investment Bank, Digistain is more than a company—it’s a movement towards equitable, effective cancer treatment. With the potential to democratize access to life-saving diagnostics, Digistain is not just envisioning a better future for cancer patients; we are actively creating it.

Facts

Industry
Healthcare / Healthcare -> Diagnostics
Location
London, England, United Kingdom
Team size
40
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works